Latest News

Non-GAAP net income surged 20.8% despite revenue headwinds in electronics.

Revenue grew 8.5% to $51.4 million as mRNA discovery demand surged.

Originations surged 60% as operating expenses fell 18% under new leadership.

Record gross margins and strong cash flow drive profitability turnaround.

China headwinds and respiratory uncertainty weigh on full-year guidance.

Portable MRI revenue surged 45% as system sales jumped 50% year over year.

Core collectibles surged 9% as management raised full-year EBITDA guidance.

ARKO acquires U.S. Petroleum Partners for $205M, expanding wholesale network.

AI-powered agentic campaigns drove 11% revenue growth.

Record profitability driven by premium growth and underwriting discipline.

Brookfield Asset Management (TSX:BAM) is down in the markets, but thriving internally.

These five financially sound companies will diversify your portfolio and generate regular payouts that supplement your primary income.

AYON adoption accelerated 22% as surgeons target GLP-1 weight-loss patients.

Liquidity plan nears completion as company executes debt paydown strategy.

UEIC returns to profitability despite 25% revenue decline, driven by aggressive cost cuts.

Circle now runs a federally regulated bank that takes no deposits and makes no loans. Here's what it actually does, and what would make it matter.

FitLife Brands (NASDAQ:FTLF) reported second-quarter 2026 revenue of $26.5 million, up 65% from a year earlier, as the company’s acquisition of Irwin Naturals more than offset declines in its Legacy FitLife business. Net income rose to $2.0 million from $1.7 million in the prior-year quarter, while

Digimarc (NASDAQ:DMRC) outlined a commercial restructuring centered on retail and consumer packaged goods, while reporting lower second-quarter revenue and annual recurring revenue following previously disclosed customer contract changes. Chief Executive Officer Paul Carreiro, who said he was 30 da

Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plan

FocalTherics (NASDAQ:FOCL) reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy. Chief Executive Officer Ryan Rhodes characterized the pe

Afya (NASDAQ:AFYA) reported first-half 2026 revenue of BRL 1.985 billion, up 7% from a year earlier, while adjusted EBITDA rose 3% to BRL 918 million. Net income increased 7% to BRL 463 million, and basic earnings per share rose 9% to BRL 5.10. Chief Executive Officer Virgilio Gibbon said the compa

DLocal (NASDAQ:DLO) reported second-quarter 2026 total payment volume of $17.7 billion, up 92% from a year earlier, as growth in ride-hailing, travel, remittances, e-commerce and other verticals drove record volume and gross profit. Chief Executive Officer Pedro Arnt said the company processed more

Regaining vaccine rights and advancing rare disease programs toward key 2026 milestones.

European review unlocks $349 million upside; net income hits $58 million.

Treasury SUI holdings hit $75.3 million as company pivots toward active ecosystem management.